advisory board

Strategic and Business Advisors:

  • Joe Belanoff, M.D.
    • CEO – Corcept Therapeutics
  • Perry Fell, Ph.D.
    • President and CEO – NanoString Technologies, Inc.
    • President and CEO – Seattle Genetics
    • Director, Molecular Immunology – Bristol-Myers Squibb
  • Stephen Hilbert, M.B.A.
    • Principal – The Rainier Group
    • Vice President – JP Morgan Asset Management
  • Alan Leong, Ph.D., M.S.E.
    • Director of Research – Biotech Stock Research
    • Director – University of Washington Center for Commercialization
  • Randall Schatzman, Ph.D.
    • CEO – Alder Biopharmaceuticals
  • Douglas Sanders, M.B.A.
    • CFO – CMC Biologics A/S
    • CFO and Head of Business Operations – Hoffmann-La Roche, Roche Consumer Health Division
    • CFO – MediQuest Therapeutics

Collaborators:

  • Caltech – Baltimore Lab
  • Seattle BioMed – HIV Vaccines Lab
  • HuMurine
  • Fred Hutchinson Cancer Research Center – Cellular Therapy Laboratory
  • The Jackson Laboratory

Clinical and Regulatory Team:

  • Richard Chin, M.D.
    • CEO – OneWorld Health
    • CEO – Oxigene
    • Head of Clinical Research – Genentech Biotherapeutics Unit
    • Author of four books on clinical trials
  • Allene Dodge
    • VP of Regulatory Affairs and Quality Assurance – Cell Therapeutics
    • Sr. Dir. of Regulatory Affairs and Quality Assurance – CV Therapeutics
    • Director of Regulatory Affairs – Genentech
  • Daniel F. Hoth, M.D.
    • Director – Seattle Genetics
    • Chief Medical Officer – Axys
    • Chief Medical Officer – Gensys
    • Director of AIDS Division – NIAID
    • Chief of the Investigational Drug Branch – NCI
  • Donna Matuizek
    • Sr. Regulatory Affairs Consultant – Harris Group
    • Sr. Manager of Contract Manufacturing – Dendreon
    • Director of Quality Control – Dendreon
  • Rick Stead, M.D.
    • VP of Clinical Research – Immunex
    • Medical Director – Amgen
    • Had significant roles in the clinical development, FDA approval, and commercialization of Epogen® and Neupogen®
  • Joyce Frey-Vasconcells, Ph.D.
    • Cell and Gene Therapy Regulatory Consulting
    • Deputy Director Office of Cellular, Tissue, and Gene Therapies – FDA
    • PharmNet Consulting

Scientific Advisors:

  • François-Loïc Cosset, Ph.D.
    • Research Director, CNRS – Viral Envelopes & Retrovirus Engineering – Ecole Normale Supérieure (ENS) de Lyon
    • Developed the novel lentiviral vector needed to transfect B lymphocytes
  • Iqbal Grewal, Ph.D., D.Sc., FRCPath (Pre-clinical Advisor)
    • VP of Pre-clinical Development – Seattle Genetics
    • Senior Scientist, Lab Head and Project Leader – Genentech
    • Has brought more than 6 molecules to clinical development.
  • Shelly Heimfeld, Ph.D.
    • Scientific Director for Cellular Therapy – Seattle Cancer Care Alliance
    • Lab Director – Fred Hutchinson Cancer Research Center
  • Hans-Peter Kiem, M.D.
    • José Carreras/E. Donnall Thomas Endowed Chair for Cancer Research – Fred Hutchinson Cancer Research Center
    • Member – Clinical Research Division, Fred Hutchinson Cancer Research Center
    • Professor of Medicine – University of Washington School of Medicine
  • Xin M. Luo, Ph.D.
    • Lead Researcher – Baltimore Lab, Caltech
    • Developed systems for engineering immunity against HIV-1.
    • Studies molecular control mechanisms of B-cell development.
  • Cliona Rooney, Ph.D.
    • Investigator – clinical trial for the iCasp9 suicide gene system
    • Expert in cellular immunotherapy